title: Risk factors for relapse after allogeneic transplantation in acute myeloid leukemia.
abstract: Acute myeloid leukemia is a clonal neoplasm derived from myeloid progenitor cells with a varying outcome. The initial goal of treatment is the achievement of complete remission, defined for over 40 years by morphology. However, without additional post-remission treatment the majority of patients relapse. In many cases of acute myeloid leukemia, allogeneic stem cell transplantation offers the best prospects of cure. In 2013, 5608 stem cell transplantations in acute myeloid leukemia were performed in Europe (5228 allogeneic and 380 autologous stem cell transplantations). Most stem cell transplantations are performed in first complete remission. However, despite a considerable reduction in the chance of relapse, in most studies, overall survival benefit of allogeneic stem cell transplantation is modest due to substantial non-relapse mortality. Here we discuss the many factors related to the risk of relapse after allogeneic stem cell transplantation.
authors.affiliation: VU University Medical Center, Amsterdam, the Netherlands g.ossenkoppele@vumc.nl.
authors.forename: Gert J
authors.initials: GJ
authors.lastname: Ossenkoppele
authors.affiliation: VU University Medical Center, Amsterdam, the Netherlands.
authors.forename: Jeroen J W M
authors.initials: JJ
authors.lastname: Janssen
authors.affiliation: VU University Medical Center, Amsterdam, the Netherlands.
authors.forename: Arjan A
authors.initials: AA
authors.lastname: van de Loosdrecht
mesh_terms: D064591:Allografts; D064592:Autografts; D018572:Disease-Free Survival; D005060:Europe / Q000453:epidemiology; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000401:mortality* / Q000628:therapy*; D012008:Recurrence; D012074:Remission Induction; D012307:Risk Factors; D033581:Stem Cell Transplantation